Head Genetics Inc. presents itself as an emerging Nashville biotech company developing a saliva-based concussion testing kit that it claims can identify traumatic brain injuries through a simple at-home sample and an AI-assisted telehealth assessment. The company markets this technology as the future of rapid concussion detection, suggesting it could transform safety protocols in youth sports, college athletics, and professional football by offering a fast, low-cost diagnostic tool. Led by founders George Gallo and Fabian Maclaren, Head Genetics promotes a storyline of innovative design, cutting-edge science, and nearly a decade of research behind its testing platform.
According to a newly filed civil lawsuit, that narrative may not be true. Investment firms Solidaris Capital LLC and Cirrus Investments LLC have sued Head Genetics, Carita Investments LLC, Parkhill, and individual defendant Mark Bianchi, alleging that the company fabricated key elements of its history, overstated its regulatory progress, and misrepresented the founders’ track records to raise investor funds. The plaintiffs claim they were induced to invest through what they describe as a sophisticated fraud scheme built on timeline deception, unverifiable scientific claims, and assurances about FDA status and technological development that appear to contradict public records and independent research.
The investment memo looked promising: a revolutionary concussion diagnostic device, nearly a decade in development, targeting a $3 billion market with technology that could save lives and generate substantial returns.
The Head Genetics Inc. founders boasted proven track records with multi-hundred-million-dollar exits. The science seemed solid, the market need undeniable. For the investors at Solidaris Capital and Cirrus Investments, it checked all the boxes—until it didn’t. Now, those investors are in court trying to recover what they allege are millions of dollars lost to an elaborate fraud scheme built on timeline manipulation, regulatory deception, and the exploitation of their trust in scientific innovation.
This is the story of how sophisticated investors fell for Head Genetics Inc., and what happened when they discovered the truth.
THE PITCH THAT HOOKED SOPHISTICATED INVESTORS
The “Tech2head Recovery” securities offering presented what appeared to be an investor’s dream: a medical device company with nearly a decade of development behind it, targeting one of healthcare’s most pressing needs. Head Genetics claimed its saliva-based concussion test could revolutionize diagnosis of traumatic brain injuries, capturing a share of a market approaching $1.75 billion and expected to reach $3 billion by 2028.
The pitch materials emphasized the founders’ credentials: George Gallo, with 20 years of branding and design experience serving blue-chip clients like LVMH and Target; and Fabian Maclaren, claiming 17 years in biotech and pharmaceutical sectors with a track record including a “$500 million exit” from a previous venture. The technology seemed validated—”FDA approved materials,” the company claimed—and the market statistics were compelling: 70 million concussion cases annually, with 40% remaining undiagnosed.
Perhaps most appealingly, the deal was structured as a charitable deduction securities offering, providing potential tax benefits alongside the investment returns. For experienced investors accustomed to complex deal structures, this appeared to be a sophisticated approach to capital raising rather than a red flag.
MEET THE VICTIMS: SOPHISTICATED INVESTORS CAUGHT OFF GUARD
Solidaris Capital LLC – This Texas-based investment firm brought decades of experience to the Head Genetics deal, including a history of successful healthcare investments. Far from naive retail investors, Solidaris Capital had the resources and expertise to conduct what they believed was thorough due diligence. Their involvement in a separate
$10 million dispute with Kingswood Capital demonstrates their active, sophisticated investment approach. Now they find themselves as lead plaintiff in a Dallas County lawsuit, fighting to recover their investment and hold the defendants accountable for what they allege was an elaborate fraud. Geoffrey Dietrich founded Solidaris Capital.
Cirrus Investments LLC – As co-plaintiff with Solidaris Capital, Cirrus Investments has been less public about the details of their involvement, but their participation in the lawsuit suggests substantial losses from the same “Tech2head Recovery” offering. Like Solidaris, they allegedly fell victim to the same timeline deception and regulatory misrepresentations that made Head Genetics appear to be a legitimate medical device company with years of validated development behind it.
THAT SINKING FEELING: THE MOMENT OF DISCOVERY
According to court documents and industry sources familiar with the situation, the unraveling began when investors started requesting specific documentation that should have been readily available for a legitimate medical device company. Clinical trial data, FDA submission records, peer-reviewed publications—the standard evidence of progress that any legitimate biotech company would eagerly share.
The discovery process was gradual but devastating. FDA database searches turned up nothing. Calls to Maclaren’s supposed previous companies went unanswered or revealed no evidence of the claimed successful exits. Most damaging of all, state incorporation records showed Head Genetics was formed in 2022, not 2013 as the company’s website claimed for its project start date.
“The timeline deception was sophisticated,” one source close to the investors described. “It wasn’t just a simple lie about when they started. They had built an entire narrative around nearly a decade of development that simply didn’t exist. By the time we realized the truth, our money was gone.”
DUE DILIGENCE THAT SEEMED THOROUGH—BUT WASN’T
The investors at Solidaris Capital and Cirrus Investments weren’t novices throwing money at a questionable opportunity. They conducted what appeared to be extensive due diligence, checking many of the boxes that experienced investors typically review. The problem wasn’t that they failed to do due diligence—it was that they trusted but didn’t verify the most critical claims.
- Technology feasibility (saliva biomarkers are legitimate science being researched)
- Business plan structure (professionally prepared with realistic assumptions)
- Financial projections (seemed reasonable for medical device market)
✗ What They Missed: - Independent FDA database verification (would have shown no approvals)
- Clinical trial registry searches (would have shown no registered studies)
- Peer-reviewed publication searches (would have shown no scientific validation)
- Documentation of prior exit claims (would have revealed unverifiable assertions)
- Company formation date confirmation (would have exposed timeline deception)
- Background checks on previous companies (would have shown limited footprint)
- Independent expert consultation on regulatory status Direct contact with supposed previous investors
THE MYSTERIOUS MARK BIANCHI
Named as a defendant alongside Head Genetics and Carita Investments, Mark Bianchi’s role in the transaction remains unclear but was apparently material enough to warrant inclusion in the lawsuit. Court documents suggest he may have served as an intermediary who introduced investors to the company, potentially serving as a gatekeeper who failed to protect the very investors who trusted his judgment.
Questions surrounding Bianchi’s involvement include what he knew about the company’s actual status, when he learned it, and whether he conducted his own due diligence before facilitating introductions. If he is the same Mark Bianchi who works as a financial advisor at Wintrust Wealth Management, his involvement raises additional questions about professional responsibility and fiduciary duty in investment referrals.
FOLLOWING THE MONEY TRAIL
Court documents reveal extensive efforts by the investors to trace what happened to their money, with discovery requests targeting a complex web of entities and individuals. The scope of these requests suggests the financial arrangements were far more complicated than a simple investment in a startup company.
Entities under investigation include Exemplar Capital LLC, Valiant Strategies Group LLC, and Valiant Investment Holdings LLC, along with individuals like Christopher Marston. Even major financial institution Morgan Stanley & Co. LLP has been subpoenaed, suggesting the money trail extends through established financial channels rather than disappearing into offshore accounts.
“We’re not just trying to recover our losses—we’re trying to understand how our money moved through such a complex web of entities. The discovery process is revealing that this was far more sophisticated than a simple startup fraud.” — Source familiar with the litigation
The forensic accounting efforts face a race against time, as court documents show emergency motions for expedited discovery and attempts to trace fund flows before assets can be further dissipated. Questions remain about what portion of investor money went to operational expenses versus personal enrichment, though the lack of actual product development activities—no clinical trials, no FDA submissions, no research partnerships—suggests minimal legitimate business spending.
THE EMOTIONAL TOLL: BEYOND FINANCIAL LOSSES
For the sophisticated investors at Solidaris Capital and Cirrus Investments, the alleged Head Genetics fraud represents more than a financial setback—it’s a professional embarrassment and a betrayal of their trust in scientific innovation. These investors have a duty to their limited partners to recover losses and explain how such an elaborate deception succeeded despite their experience and resources.
The impact extends beyond the immediate victims to their professional relationships, fund performance, and willingness to pursue future medical device investments. The alleged fraud has created a ripple effect of increased skepticism that may ultimately harm legitimate biotech companies seeking capital.
THE PATTERN: MACLAREN’S PREVIOUS VENTURES
As investors dug deeper into Fabian Maclaren’s background, disturbing patterns emerged regarding his previous companies. Essential Citizen, Inc., where Maclaren served as CEO from December 2021 to January 2025, has little public information available and unclear current status. Genesis Laboratories Inc., where he claimed to be CEO from 2015-2019, similarly lacks publicly available information about operations, exit, or current status.
Most concerning are the questions these discoveries raised: Were there other investors in these previous companies who experienced similar issues? Is there a pattern of behavior across multiple ventures? What really happened to the claimed “$500 million exit” that was part of Maclaren’s credentials?
Attempts to locate and interview previous investors have been unsuccessful, raising additional questions about whether Head Genetics represents an isolated incident or part of a broader pattern of questionable business practices.
THE NASHVILLE CONNECTION
The Head Genetics fraud has sent shockwaves through Nashville’s growing biotech ecosystem, raising questions about how such an elaborate scheme operated in a business community known for its collaborative approach to entrepreneurship. Local incubators, accelerators, and networking events are now grappling with questions about their role in vetting companies and protecting the ecosystem from bad actors.
Legitimate Nashville biotech companies have been quick to distance themselves from Head Genetics while emphasizing their own proper FDA compliance. The incident has prompted discussions about better vetting procedures at networking events and the responsibility of the business community to police itself against fraudulent actors.
THE LEGAL BATTLE: TWO JURISDICTIONS, COMPLEX DISCOVERY
The investors’ legal fight is playing out in two jurisdictions, with the primary case filed December 10, 2024, in Dallas County, Texas (Case No. DC-24-21484), and additional proceedings in Cook County, Illinois (Case No. 2025-L-010360), filed August 18, 2025. The multi-jurisdictional approach suggests the interstate nature of the alleged fraud and provides additional discovery opportunities.
| Case Element | Dallas County, TX | Cook County, IL |
| Filing Date | December 10, 2024 | August 18, 2025 |
| Case Status | OPEN – Actively Litigated | OPEN – Discovery Phase |
| KeyDefendants | Head Genetics, Carita Investments, Mark Bianchi | Same defendants, expanded jurisdiction |
| Case Type | “Failed charitable deduction securities offering” | Discovery – Civil |
RECOVERY PROSPECTS: MANAGING EXPECTATIONS
Securities attorneys familiar with fraud cases provide a sobering assessment of recovery prospects for the Head Genetics investors. Recovery rates in fraud cases typically range from 10-30% at best, and depend heavily on locating and recovering assets before they can be dissipated or hidden.
The obstacles are significant: Head Genetics has no revenue or ongoing operations, the founders may have limited personal assets, and the complex entity structure makes tracing difficult. International elements suggested by the letters rogatory requests complicate enforcement, while legal fees continue to consume resources that might otherwise be recovered.
The timeline for any recovery is measured in years, not months, with 3-5 years representing a minimum expectation for resolution. Even then, criminal restitution proceedings often prove more effective than civil judgments in fraud cases, making cooperation with potential criminal investigations crucial for maximizing recovery.
LESSONS LEARNED: WHAT INVESTORS WOULD DO DIFFERENTLY
The Head Genetics fraud has become a case study in how sophisticated investors can be deceived by elaborate schemes that exploit their trust in scientific innovation. The investors involved have shared their painful lessons learned, hoping to prevent other investors from falling victim to similar frauds.
Their recommendations for other investors considering biotech deals are specific and actionable: Always verify FDA claims independently on government websites, demand
proof of prior exits with documentation and verification, verify company formation dates with state records, and search ClinicalTrials.gov for any company claiming device development.
EXPERT ADVICE: RECOGNIZING SOPHISTICATED FRAUD
Fraud investigators and securities attorneys who have reviewed the Head Genetics case identify several patterns that other investors should recognize. Timeline manipulation is a classic fraud indicator, particularly when vague claims about prior successes lack specific documentation. The mixing of legitimate science with fraudulent business practices is a common pattern designed to exploit investors’ optimism about innovation.
Medical device investment experts emphasize that no FDA approval after 10 years of claimed development should be an automatic deal-breaker. Publications are free to produce and their absence is a huge red flag, while clinical trials are expensive but necessary—no trials should mean no investment.
THE HUMAN COST: FAMILIES AND RELATIONSHIPS
The impact of the Head Genetics fraud extends beyond professional embarrassment to personal relationships and family finances. For institutional investors, the losses affect fund performance and relationships with limited partners. The stress of being defrauded, combined with the time and energy diverted to litigation, takes a toll that extends far beyond the immediate financial losses.
Some victims of major investment frauds require therapy and counseling to cope with the emotional impact of being deceived. The experience affects their willingness to trust future investment opportunities and can strain marriages and professional relationships as they struggle to explain how sophisticated due diligence failed to prevent the fraud.
THE PSYCHOLOGY OF SOPHISTICATED VICTIMS
Understanding why experienced investors fall for elaborate frauds requires examining the psychological factors that sophisticated schemes exploit. Optimism bias leads investors to want to believe in innovation, while confirmation bias causes them to see what they want to see in investment materials. Authority bias makes them trust credentials and titles, while complexity confusion allows sophisticated schemes to overwhelm normal scrutiny.
Social proof—the involvement of other seemingly sophisticated investors—provides false comfort, while time pressure built into deal structures prevents thorough
investigation. The Head Genetics fraud exploited all of these psychological vulnerabilities in a coordinated scheme designed to overwhelm normal due diligence processes.
VICTIM ADVOCACY: PREVENTING FUTURE FRAUDS
The investors in Head Genetics have transformed their painful experience into advocacy for stronger investor protections and better fraud prevention. They’re warning others in the investment community, sharing lessons learned publicly through their lawsuit, and cooperating with potential regulatory investigations.
Their efforts to connect with other potential victims and advocate for regulatory changes represent an attempt to create positive outcomes from their negative experience. By speaking with journalists and exposing the sophisticated tactics used against them, they’re performing a public service that extends beyond their own financial recovery.
THE FOUNDERS’ SILENCE SPEAKS VOLUMES
Perhaps most telling in the entire Head Genetics saga is the complete silence from founders George Gallo and Fabian Maclaren. Neither has responded to investor inquiries, returned calls from journalists, or made any public statement about the lawsuit and allegations against them. Their LinkedIn profiles continue to show Head Genetics roles, but there’s no evidence of any attempt to make investors whole or explain the discrepancies that led to the fraud allegations.
The company website remains active but contains no updates about the litigation or explanations for the timeline discrepancies that form the basis of the fraud allegations. This pattern of avoidance and silence, rather than engagement and explanation, suggests a consciousness of guilt that speaks louder than any denial might.
LOOKING FORWARD: RECOVERY AND PREVENTION
The Head Genetics case is still in its early stages, with years of litigation likely ahead. In the short term, the discovery process will reveal the full extent of the alleged misrepresentations and potentially identify additional defendants or victims. Criminal investigation referrals are possible, and regulatory enforcement actions may follow.
Medium-term prospects include trial or arbitration proceedings, expert testimony on fraud elements, and damages calculations. Parallel criminal proceedings and regulatory
About Head Genetics Inc.
Headquarters: Nashville, TN
Phone: (832) 217-8585
Email: admin@optihealthmanagement.com
Company Website: https://headgenetics.com/